Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Daniel P. Cahill, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Daniel Cahill and Sandro Santagata.
Connection Strength

0.977
  1. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
    View in: PubMed
    Score: 0.181
  2. Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathol Commun. 2014 Dec 24; 2:167.
    View in: PubMed
    Score: 0.155
  3. Sporadic multiple meningiomas harbor distinct driver mutations. Acta Neuropathol Commun. 2021 01 06; 9(1):8.
    View in: PubMed
    Score: 0.059
  4. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol Commun. 2020 10 21; 8(1):171.
    View in: PubMed
    Score: 0.058
  5. Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. Acta Neuropathol. 2020 07; 140(1):89-93.
    View in: PubMed
    Score: 0.056
  6. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020 04; 52(4):371-377.
    View in: PubMed
    Score: 0.056
  7. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer. 2019 09 01; 125(17):2910-2914.
    View in: PubMed
    Score: 0.053
  8. Updates in prognostic markers for gliomas. Neuro Oncol. 2018 11 09; 20(suppl_7):vii17-vii26.
    View in: PubMed
    Score: 0.051
  9. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018 11; 136(5):779-792.
    View in: PubMed
    Score: 0.050
  10. Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. NPJ Precis Oncol. 2017; 1(1):5.
    View in: PubMed
    Score: 0.045
  11. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy. Neurosurg Focus. 2016 Dec; 41(6):E2.
    View in: PubMed
    Score: 0.044
  12. Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. J Neurosurg. 2017 08; 127(2):438-444.
    View in: PubMed
    Score: 0.044
  13. Treatment of brain metastases in the modern genomic era. Pharmacol Ther. 2017 02; 170:64-72.
    View in: PubMed
    Score: 0.044
  14. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.041
  15. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.